Search Results for "Screening"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Screening. Results 41 to 50 of 140 total matches.

Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
for colorectal cancer screening in the US. Many patients consider cleansing the bowel in preparation ...
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The ready-to-drink solution contains the same ingredients as Prepopik, which is supplied as a powder for reconstitution.
Med Lett Drugs Ther. 2018 May 21;60(1547):84-6 |  Show IntroductionHide Introduction

Tafenoquine (Arakoda; Krintafel) for Malaria

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
of P. vivax4,9 32.00 tafenoquine succinate) 300 mg once 1. All patients must be screened for glucose ...
The oral antimalarial tafenoquine succinate, a long-acting analog of primaquine, has been approved by the FDA in 2 different strengths. Arakoda (100-mg tablets; Sixty Degrees) is indicated for the prophylaxis of malaria in adults. Krintafel (150-mg tablets; GSK) is indicated for the prevention of relapse (radical cure) of Plasmodium vivax malaria in patients ≥16 years old undergoing treatment for acute P. vivax infection.
Med Lett Drugs Ther. 2019 Jul 1;61(1575):101-4 |  Show IntroductionHide Introduction

In Brief: New Indications for Secukinumab (Cosentyx)

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016  (Issue 1496)
who received placebo. Patients should be screened for tuberculosis before starting therapy ...
The FDA has approved the subcutaneous IL-17A antagonist secukinumab (Cosentyx - Novartis), which was first approved in 2015 for treatment of plaque psoriasis, for treatment of psoriatic arthritis and ankylosing spondylitis in adults.1 Secukinumab is one of the most effective drugs available for treatment of plaque psoriasis.2FDA approval of secukinumab for treatment of psoriatic arthritis was based on two randomized, double-blind trials with a primary endpoint of at least a 20% improvement in the American College of Rheumatology response criteria (ACR20) at 24 weeks. In both trials, ACR20...
Med Lett Drugs Ther. 2016 Jun 6;58(1496):76 |  Show IntroductionHide Introduction

In Brief: Hepatitis B Reactivation with Direct-Acting Antiviral Drugs for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Oct 24, 2016  (Issue 1506)
with direct-acting antiviral drugs for HCV is unknown. Patients should be screened for current or past HBV ...
The FDA recently announced that it will require the labeling of all direct-acting antiviral drugs used for treatment of hepatitis C virus (HCV) infection to include a boxed warning about a risk of hepatitis B virus (HBV) reactivation associated with their use.1Twenty-four cases of HBV reactivation occurring during treatment with direct-acting antiviral drugs for HCV were identified from the FDA Adverse Event Reporting System and the medical literature.2-5 Before starting direct-acting antiviral treatment for HCV, some of these patients were hepatitis B surface antigen (HbsAG) positive and...
Med Lett Drugs Ther. 2016 Oct 24;58(1506):140 |  Show IntroductionHide Introduction

Diagnostic Tests for HIV

   
The Medical Letter on Drugs and Therapeutics • Aug 29, 1997  (Issue 1008)
for antibodies, as the primary screening test for HIV infection. Reactive ELISAs are repeated in duplicate ...
Diagnostic tests for human immunodeficiency virus (HIV) infection use four approaches: identification of antibodies to viral proteins, detection of viral antigens, detection of viral nucleic acids, and culturing the virus (CJ Schleupner in GL Mandell et al, eds, Principles and Practice of Infectious Diseases, 4th ed, New York:Churchill Livingstone, 1995, page 1253). In recent years, the FDA has approved the use of a 10- minute blood test, two home collection kits, and office tests that use urine and oral secretions to diagnose HIV infection. One home test, Confide (Johnson & Johnson), was...
Med Lett Drugs Ther. 1997 Aug 29;39(1008):81-3 |  Show IntroductionHide Introduction

SSRIs and Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007  (Issue 1274)
recommends that women >65 years old be screened for osteoporosis. 7 Whether younger patients taking SSRIs ...
Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is biologically plausible because bone has serotonin receptors, and SSRI-treated mice have reduced bone mass.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):95-6 |  Show IntroductionHide Introduction

Triumeq: A 3-Drug Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
occurs. Screening for the HLA-B*5701 allele, which is associated Table 1. Regimens for Treatment-Naive ...
The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine, for once-daily treatment of HIV-1 infection. Dolutegravir (Tivicay) was approved as a single agent in 2013.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):7-8 |  Show IntroductionHide Introduction

Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023  (Issue 1692)
of several well-validated screening tests, PPD often goes undetected and untreated.2 A selective serotonin ...
The FDA has approved the oral GABAA receptor modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression (PPD). Zuranolone is the second drug to be approved for this indication; brexanolone (Zulresso), another GABAA receptor modulator, was approved for IV treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3   doi:10.58347/tml.2023.1692a |  Show IntroductionHide Introduction

Drugs for Dry Eye Disease

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025  (Issue 1723)
dysfunction, poor eyelid function, environmental factors, extended screen time, inflammatory conditions ...
Disruption of tear-film homeostasis (altered composition, reduced production, rapid evaporation) and resulting ocular surface inflammation cause the discomfort and blurred vision of dry eye disease. Many cases are caused by tear evaporation due to meibomian gland dysfunction. Other precipitating factors can include lacrimal gland dysfunction, poor eyelid function, environmental factors, extended screen time, inflammatory conditions such as Sjögren's syndrome, and use of some ocular or systemic drugs such as antihistamines, retinoids, or selective serotonin reuptake inhibitors...
Med Lett Drugs Ther. 2025 Mar 3;67(1723):35-7   doi:10.58347/tml.2025.1723b |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
, but not of etanercept ▶ Screen for TB before starting and annually thereafter ▶ Biosimilars are available for Humira ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction